Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 2 , ISSUE 3 ( September-December, 2010 ) > List of Articles

REVIEW ARTICLE

Ovulation Induction in Anovulatory Patients with Polycystic Ovary Syndrome

Angela Falbo, Stefano Palomba, Tiziana Russo, Annalisa Di Cello, Fulvio Zullo

Citation Information : Falbo A, Palomba S, Russo T, Cello AD, Zullo F. Ovulation Induction in Anovulatory Patients with Polycystic Ovary Syndrome. J South Asian Feder Obs Gynae 2010; 2 (3):175-182.

DOI: 10.5005/jp-journals-10006-1092

Published Online: 01-12-2010

Copyright Statement:  Copyright © 2010; The Author(s).


Abstract

PDF Share
  1. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Given JR, Haseltine F, Merriam GR (Eds). Polycystic ovary syndrome. Boston: Blackwell 1992;377-84.
  2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
  3. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-49.
  4. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004;10:267-80.
  5. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online 2004;8: 431-39.
  6. Polycystic ovary syndrome: A changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
  7. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
  8. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36: 105-11.
  9. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604.
  10. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84: 1470-74.
  11. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-12.
  12. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-05.
  13. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1086-91.
  14. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-19.
  15. Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA 1998;279:669-74.
  16. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3:359-65.
  17. Clomiphene citrate: Mechanism(s) and site(s) of action: A hypothesis revisited. Fertil Steril 1984;42:331-44.
  18. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril 1991;56:465-68.
  19. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5:670-74.
  20. Clomiphene citrate directly impairs endometrial receptivity in the mouse. Fertil Steril 1990;53:727-31.
  21. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992;99:1008-13.
  22. Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination. Reprod Biomed Online 2004;8:115-18.
  23. The effect of ethinyl estradiol on endometrial thickness and uterine volume during ovulation induction by clomiphene citrate. Fertil Steril 1992;57:33-36.
  24. Endometrial development was improved by transdermal estradiol in patients treated with clomiphene citrate. Gynecol Obstet Invest 1999;47:251-54.
  25. Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: A comparative, randomized study. Fertil Steril 2000;73:85-89.
  26. Clomiphene citrate augments follicle stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. Fertil Steril 1987;47: 334-40.
  27. Clomiphene citrate induced perturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes in vivo and in vitro. Fertil Steril 2000;73:620-26.
  28. The reincarnation of an old question clomid effect on oocyte and embryo? Fertil Steril 2000;73:620-26.
  29. Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility. Obstet Gynecol 1995;86:917-21.
  30. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000;3.
  31. Cost-effective infertility care. Hum Reprod Update 2000;6:190-99.
  32. Managing the anovulatory state: Medical induction of ovulation. Number 197 September 1994. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. Number 197 September 1994. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1994;47:305-12.
  33. Induction of ovulation with purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome. Am J Obstet Gynecol 1985;151:635-40.
  34. Pure FSH for ovulation induction in patients with polycystic ovary syndrome and resistant to clomiphene citrate therapy. Hum Reprod 1991;6:218-21.
  35. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000;4.
  36. Recombinant FSH vs urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001;2.
  37. Recombinant vs urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: A safer and more effective treatment. Horm Res 2001;55:224-28.
  38. Low-dose FSH stimulation in polycystic ovary syndrome: Comparison of 3 FSH preparations. Exp Clin Endocrinol Diabetes 1998;106: 435-39.
  39. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome. Cochrane Database Syst Rev 2000;2.
  40. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
  41. Minilaparoscopic ovarian drilling under local anesthesia in patients with polycystic ovary syndrome. Fertil Steril 2000;74:376-79.
  42. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984;41: 20-25.
  43. Laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome. J Am Assoc Gynecol Laparosc 2001;8:511-18.
  44. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: Endocrine and ultrasonographic outcomes. Hum Reprod 2002;17:2851-57.
  45. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 1999;84:4278-82.
  46. Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome. Fertil Steril 2000;74:585-88.
  47. Effects of laparoscopic ovarian drilling on adrenal steroids in polycystic ovary syndrome patients with and without hyperinsulinemia. Fertil Steril 2001;75:501-04.
  48. Characteristics predictive of response to ovarian diathermy in women with polycystic ovarian syndrome. Am J Obstet Gynecol 2003;188:1171-73.
  49. Ovarian electrocautery vs human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin Endocrinol (Oxf) 1990;33:585-92.
  50. Laparoscopic “Drilling” by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2001;4.
  51. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: Randomised controlled trial. BMJ 2004;328:192
  52. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod 2004;19:1741-45.
  53. The use of laparoscopic ovarian electrocautery in preventing cancellation of in vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 1997;12:1443-47.
  54. In vitro fertilization following laparoscopic ovarian diathermy in women with polycystic ovarian syndrome. Acta Obstet Gynecol Scand 1997;76:555-58.
  55. Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. Fertil Steril. Fertil Steril 2003;79:938-41.
  56. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebocontrolled trial. J Clin Endocrinol Metab 2004;89: 4801-09.
  57. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13.
  58. Editorial: Metformin—comparison with other therapies in ovulation induction in polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4797-800.
  59. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-74.
  60. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-79.
  61. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries: A randomized, double blinded placebo controlled trial. Hum Reprod 2001;16:1625-31.
  62. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
  63. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60.
  64. Metformin monotherapy in lean women with polycystic ovary syndrome. R & Pro D. Biomed Online 2005;10:100-04.
  65. Effects of diet and metformin administration on sex hormone binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-62.
  66. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
  67. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-30.
  68. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282-85.
  69. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: A prospective randomized trial. Hum Reprod 2002;17:289-94.
  70. A randomized controlled trial evaluating metformin pretreatment and coadministration in nonobese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian hyperstimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005 Jun 15 (Epub ahead of print).
  71. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505-09.
  72. Impact of metformin therapy on ovarian stimulation and outcome in ‘coasted’ patients with polycystic ovary syndrome undergoing in vitro fertilization. Reprod Biomed Online 2002;5:112-16.
  73. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce firsttrimester spontaneous abortion: A pilot study. Fertil Steril 2001;75:46-52.
  74. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-06.
  75. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990;33:2933-42.
  76. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J Steroid Biochem Mol Biol 1993;44:375-87.
  77. Are estrogens of import to primate/human ovarian folliculogenesis? Endocr Rev 2001;22:389-424.
  78. Androgen and follicle stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84:2951-56.
  79. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-29.
  80. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992;13:641-69.
  81. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs 2003;12:353-71.
  82. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005;192:381-86.
  83. The use of aromatase inhibitor for induction of ovulation in cases of clomiphene citrate failure. Curr Opin Obstet Gynecol 2002;14:255-63.
  84. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305-09.
  85. Prospective randomised trial comparing the effects of letrazole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation prior to intrauterine insemination (IUI). Fertil Steril 2001;76(Suppl 1):S110.
  86. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril 2005;83:229-31.
  87. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002;78:280-85.
  88. Clomiphene citrate vs letrozole for ovarian stimulation: A pilot study. Reprod Biomed Online 2003;7:543-46.
  89. Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. Mol Reprod Dev 2002;61: 549-59.
  90. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol 1997;61:157-66.
  91. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003;18:1588-97.
  92. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002;77:776-80.
  93. A randomized single blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: A preliminary report. Hum Reprod 2004;19:2031-35.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.